0

Close
 
Upcoming Allied Market Research
2023
Immunodermatology Market

Immunodermatology Market

by Type (Systemic sclerosis, Dermatomyositis, Psoriasis, Vitiligo, Alopecia areata, Lichen sclerosus, Allergic Dermatitis, Atopic Dermatitis, Lupus erythematosus, Blistering diseases, Connective tissue diseases), by Diagnosis (Immunofluorescence Testing, Biopsy, Blood Test), by Therapy (Drug Therapy, Intensed Pulsed Light (IPL)Therapy, Stem Cell Therapy, Gene Therapy) and by Route of Administration (Oral, Topical, Intravenous): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A12596
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Immunodermatology Market

Request Now !

Immunodermatology is a medical specialization that concentrates on diagnosing and treating skin disorders characterized by responses that influence the body's immune system. Immunodermatology testing is essential in the diagnosis and treatment of many diseases afflicting the epithelial organs including the skin, intestines, respiratory tract, and mucous membranes. Skin fights antigens on T cells and produces various types of cytokines because the skin is the body's first defective organ. From newborns to the elderly, skin diseases affect patients at any time, and they can be chronic or acute, genetic or conditional, and painful or painless. Numerous factors including the surge in demand for early diagnosis of skin conditions, increase in geriatric population, enhanced health insurance, and raised disposal income are linked with the expansion of immunodermatology market size.

COVID-19 Impact analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the immunodermatology market.

Top Impacting Factors

  • Increase in cases of cardiovascular diseases, surge in geriatric populations, rise in demand for minimally invasive procedure & advanced cardiovascular treatment and procedures such as balloon angioplasty are factors that drive the growth of the angioplasty balloons market
  • In addition, increase in healthcare expenditure; availability of skilled professionals; collaborations & partnerships between key players to facilitate drug development; rise in R&D activities to improve quality of drugs; launch of novel developed drug in market; and technological development such as imaging technologies, drug-eluting, and cutting balloons are some factors, which boost the market growth for angioplasty balloons
  • However, lack of knowledge for proper handling of the device as well as side effects and associated complications hinder the market growth.
  • Contrarily, favorable reimbursement policies and support from government for regulatory approval present new pathways in the industry

Market Trends

New product launches to flourish the market

In May 2019, UCB, a global biopharmaceutical company, received FDA approval for the UCB’s tumor necrosis factor (TNF) inhibitor Cimzia (certolizumab pegol) to treat adults with moderate-to-severe plaque psoriasis. This approval indicates UCB’s path into the immuno-dermatology market.

In December 2020, Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company announced that they are focusing on the development and commercialized treatments for unmet needs in immune-mediated dermatological diseases and conditions. The robust pipeline involves 4 development programs addressing 7 dermatological diseases, which includes 3 programs in Phase 2 or Phase 3 for 5 different indications.

Key Benefits of the Report

  • This study presents the analytical depiction of the immunodermatology industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the immunodermatology market share.
  • The current market is quantitatively analyzed to highlight the immunodermatology market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed immunodermatology market analysis based on competitive intensity and how the competition will take shape in coming years

Questions answered in the immunodermatology  Report

  • Which are the leading players active in the immunodermatology market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "Immunodermatology"?
  • What is "Immunodermatology" Market prediction in the future?
  • Who are the leading global players in the "Immunodermatology" Market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "Immunodermatology" Market report?

 Immunodermatology Market Report Highlights

Aspects Details
By Type
  • Systemic sclerosis
  • Dermatomyositis
  • Psoriasis
  • Vitiligo
  • Alopecia areata
  • Lichen sclerosus
  • Allergic Dermatitis
  • Atopic Dermatitis
  • Lupus erythematosus
  • Blistering diseases
  • Connective tissue diseases
By Diagnosis
  • Immunofluorescence Testing
    • Direct
    • Indirect
  • Biopsy
  • Blood Test
By Therapy
  • Drug Therapy
    • Corticosteroids
    • Immunosuppressant
    • Calcineurin Inhibitors
    • TNF Alfa Inhibitors
    • Interleukin Inhibitors
    • Antibiotics
  • Intensed Pulsed Light (IPL)Therapy
  • Stem Cell Therapy
  • Gene Therapy
By Route of Administration
  • Oral
  • Topical
  • Intravenous
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Glenmark Pharmaceuticals Inc., Bausch Health, Astellas Pharma, Valeant Pharmaceuticals, Prometheus Laboratories, Novopharm Limited, Abbvie, Aspen Pharmacare Inc., Taro Pharmaceuticals Inc., Novartis
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: IMMUNODERMATOLOGY MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Systemic Sclerosis

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Dermatomyositis

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Psoriasis

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Vitiligo

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Alopecia Areata

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Lichen Sclerosus

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Allergic Dermatitis

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. Atopic Dermatitis

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

    • 4.10. Lupus Erythematosus

      • 4.10.1. Key Market Trends, Growth Factors and Opportunities

      • 4.10.2. Market Size and Forecast, By Region

      • 4.10.3. Market Share Analysis, By Country

    • 4.11. Blistering Diseases

      • 4.11.1. Key Market Trends, Growth Factors and Opportunities

      • 4.11.2. Market Size and Forecast, By Region

      • 4.11.3. Market Share Analysis, By Country

    • 4.12. Connective Tissue Diseases

      • 4.12.1. Key Market Trends, Growth Factors and Opportunities

      • 4.12.2. Market Size and Forecast, By Region

      • 4.12.3. Market Share Analysis, By Country

  • CHAPTER 5: IMMUNODERMATOLOGY MARKET, BY DIAGNOSIS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Diagnosis

    • 5.2. Immunofluorescence Testing

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

      • 5.2.4. Direct

        • 5.2.4.1. Market Size and Forecast

      • 5.2.4. Indirect

        • 5.2.4.1. Market Size and Forecast

    • 5.3. Biopsy

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Blood Test

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: IMMUNODERMATOLOGY MARKET, BY THERAPY

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Therapy

    • 6.2. Drug Therapy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

      • 6.2.4. Corticosteroids

        • 6.2.4.1. Market Size and Forecast

      • 6.2.4. Immunosuppressant

        • 6.2.4.1. Market Size and Forecast

      • 6.2.4. Calcineurin Inhibitors

        • 6.2.4.1. Market Size and Forecast

      • 6.2.4. TNF Alfa Inhibitors

        • 6.2.4.1. Market Size and Forecast

      • 6.2.4. Interleukin Inhibitors

        • 6.2.4.1. Market Size and Forecast

      • 6.2.4. Antibiotics

        • 6.2.4.1. Market Size and Forecast

    • 6.3. Intensed Pulsed Light (IPL)Therapy

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Stem Cell Therapy

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Gene Therapy

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: IMMUNODERMATOLOGY MARKET, BY ROUTE OF ADMINISTRATION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Route Of Administration

    • 7.2. Oral

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Topical

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Intravenous

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: IMMUNODERMATOLOGY MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Type

      • 8.2.3. Market Size and Forecast, By Diagnosis

      • 8.2.4. Market Size and Forecast, By Therapy

      • 8.2.5. Market Size and Forecast, By Route Of Administration

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Immunodermatology Market

        • 8.2.7.1. Market Size and Forecast, By Type
        • 8.2.7.2. Market Size and Forecast, By Diagnosis
        • 8.2.7.3. Market Size and Forecast, By Therapy
        • 8.2.7.4. Market Size and Forecast, By Route Of Administration

      • 8.2.8. Canada Immunodermatology Market

        • 8.2.8.1. Market Size and Forecast, By Type
        • 8.2.8.2. Market Size and Forecast, By Diagnosis
        • 8.2.8.3. Market Size and Forecast, By Therapy
        • 8.2.8.4. Market Size and Forecast, By Route Of Administration

      • 8.2.9. Mexico Immunodermatology Market

        • 8.2.9.1. Market Size and Forecast, By Type
        • 8.2.9.2. Market Size and Forecast, By Diagnosis
        • 8.2.9.3. Market Size and Forecast, By Therapy
        • 8.2.9.4. Market Size and Forecast, By Route Of Administration

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Type

      • 8.3.3. Market Size and Forecast, By Diagnosis

      • 8.3.4. Market Size and Forecast, By Therapy

      • 8.3.5. Market Size and Forecast, By Route Of Administration

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Immunodermatology Market

        • 8.3.7.1. Market Size and Forecast, By Type
        • 8.3.7.2. Market Size and Forecast, By Diagnosis
        • 8.3.7.3. Market Size and Forecast, By Therapy
        • 8.3.7.4. Market Size and Forecast, By Route Of Administration

      • 8.3.8. Germany Immunodermatology Market

        • 8.3.8.1. Market Size and Forecast, By Type
        • 8.3.8.2. Market Size and Forecast, By Diagnosis
        • 8.3.8.3. Market Size and Forecast, By Therapy
        • 8.3.8.4. Market Size and Forecast, By Route Of Administration

      • 8.3.9. Italy Immunodermatology Market

        • 8.3.9.1. Market Size and Forecast, By Type
        • 8.3.9.2. Market Size and Forecast, By Diagnosis
        • 8.3.9.3. Market Size and Forecast, By Therapy
        • 8.3.9.4. Market Size and Forecast, By Route Of Administration

      • 8.3.10. Spain Immunodermatology Market

        • 8.3.10.1. Market Size and Forecast, By Type
        • 8.3.10.2. Market Size and Forecast, By Diagnosis
        • 8.3.10.3. Market Size and Forecast, By Therapy
        • 8.3.10.4. Market Size and Forecast, By Route Of Administration

      • 8.3.11. UK Immunodermatology Market

        • 8.3.11.1. Market Size and Forecast, By Type
        • 8.3.11.2. Market Size and Forecast, By Diagnosis
        • 8.3.11.3. Market Size and Forecast, By Therapy
        • 8.3.11.4. Market Size and Forecast, By Route Of Administration

      • 8.3.12. Russia Immunodermatology Market

        • 8.3.12.1. Market Size and Forecast, By Type
        • 8.3.12.2. Market Size and Forecast, By Diagnosis
        • 8.3.12.3. Market Size and Forecast, By Therapy
        • 8.3.12.4. Market Size and Forecast, By Route Of Administration

      • 8.3.13. Rest Of Europe Immunodermatology Market

        • 8.3.13.1. Market Size and Forecast, By Type
        • 8.3.13.2. Market Size and Forecast, By Diagnosis
        • 8.3.13.3. Market Size and Forecast, By Therapy
        • 8.3.13.4. Market Size and Forecast, By Route Of Administration

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Type

      • 8.4.3. Market Size and Forecast, By Diagnosis

      • 8.4.4. Market Size and Forecast, By Therapy

      • 8.4.5. Market Size and Forecast, By Route Of Administration

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Immunodermatology Market

        • 8.4.7.1. Market Size and Forecast, By Type
        • 8.4.7.2. Market Size and Forecast, By Diagnosis
        • 8.4.7.3. Market Size and Forecast, By Therapy
        • 8.4.7.4. Market Size and Forecast, By Route Of Administration

      • 8.4.8. Japan Immunodermatology Market

        • 8.4.8.1. Market Size and Forecast, By Type
        • 8.4.8.2. Market Size and Forecast, By Diagnosis
        • 8.4.8.3. Market Size and Forecast, By Therapy
        • 8.4.8.4. Market Size and Forecast, By Route Of Administration

      • 8.4.9. India Immunodermatology Market

        • 8.4.9.1. Market Size and Forecast, By Type
        • 8.4.9.2. Market Size and Forecast, By Diagnosis
        • 8.4.9.3. Market Size and Forecast, By Therapy
        • 8.4.9.4. Market Size and Forecast, By Route Of Administration

      • 8.4.10. South Korea Immunodermatology Market

        • 8.4.10.1. Market Size and Forecast, By Type
        • 8.4.10.2. Market Size and Forecast, By Diagnosis
        • 8.4.10.3. Market Size and Forecast, By Therapy
        • 8.4.10.4. Market Size and Forecast, By Route Of Administration

      • 8.4.11. Australia Immunodermatology Market

        • 8.4.11.1. Market Size and Forecast, By Type
        • 8.4.11.2. Market Size and Forecast, By Diagnosis
        • 8.4.11.3. Market Size and Forecast, By Therapy
        • 8.4.11.4. Market Size and Forecast, By Route Of Administration

      • 8.4.12. Thailand Immunodermatology Market

        • 8.4.12.1. Market Size and Forecast, By Type
        • 8.4.12.2. Market Size and Forecast, By Diagnosis
        • 8.4.12.3. Market Size and Forecast, By Therapy
        • 8.4.12.4. Market Size and Forecast, By Route Of Administration

      • 8.4.13. Malaysia Immunodermatology Market

        • 8.4.13.1. Market Size and Forecast, By Type
        • 8.4.13.2. Market Size and Forecast, By Diagnosis
        • 8.4.13.3. Market Size and Forecast, By Therapy
        • 8.4.13.4. Market Size and Forecast, By Route Of Administration

      • 8.4.14. Indonesia Immunodermatology Market

        • 8.4.14.1. Market Size and Forecast, By Type
        • 8.4.14.2. Market Size and Forecast, By Diagnosis
        • 8.4.14.3. Market Size and Forecast, By Therapy
        • 8.4.14.4. Market Size and Forecast, By Route Of Administration

      • 8.4.15. Rest of Asia Pacific Immunodermatology Market

        • 8.4.15.1. Market Size and Forecast, By Type
        • 8.4.15.2. Market Size and Forecast, By Diagnosis
        • 8.4.15.3. Market Size and Forecast, By Therapy
        • 8.4.15.4. Market Size and Forecast, By Route Of Administration

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Type

      • 8.5.3. Market Size and Forecast, By Diagnosis

      • 8.5.4. Market Size and Forecast, By Therapy

      • 8.5.5. Market Size and Forecast, By Route Of Administration

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Immunodermatology Market

        • 8.5.7.1. Market Size and Forecast, By Type
        • 8.5.7.2. Market Size and Forecast, By Diagnosis
        • 8.5.7.3. Market Size and Forecast, By Therapy
        • 8.5.7.4. Market Size and Forecast, By Route Of Administration

      • 8.5.8. South Africa Immunodermatology Market

        • 8.5.8.1. Market Size and Forecast, By Type
        • 8.5.8.2. Market Size and Forecast, By Diagnosis
        • 8.5.8.3. Market Size and Forecast, By Therapy
        • 8.5.8.4. Market Size and Forecast, By Route Of Administration

      • 8.5.9. Saudi Arabia Immunodermatology Market

        • 8.5.9.1. Market Size and Forecast, By Type
        • 8.5.9.2. Market Size and Forecast, By Diagnosis
        • 8.5.9.3. Market Size and Forecast, By Therapy
        • 8.5.9.4. Market Size and Forecast, By Route Of Administration

      • 8.5.10. UAE Immunodermatology Market

        • 8.5.10.1. Market Size and Forecast, By Type
        • 8.5.10.2. Market Size and Forecast, By Diagnosis
        • 8.5.10.3. Market Size and Forecast, By Therapy
        • 8.5.10.4. Market Size and Forecast, By Route Of Administration

      • 8.5.11. Argentina Immunodermatology Market

        • 8.5.11.1. Market Size and Forecast, By Type
        • 8.5.11.2. Market Size and Forecast, By Diagnosis
        • 8.5.11.3. Market Size and Forecast, By Therapy
        • 8.5.11.4. Market Size and Forecast, By Route Of Administration

      • 8.5.12. Rest of LAMEA Immunodermatology Market

        • 8.5.12.1. Market Size and Forecast, By Type
        • 8.5.12.2. Market Size and Forecast, By Diagnosis
        • 8.5.12.3. Market Size and Forecast, By Therapy
        • 8.5.12.4. Market Size and Forecast, By Route Of Administration

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Novartis

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Abbvie

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Valeant Pharmaceuticals

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Bausch Health

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Glenmark Pharmaceuticals Inc.

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Astellas Pharma

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Novopharm Limited

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Aspen Pharmacare Inc.

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Prometheus Laboratories

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Taro Pharmaceuticals Inc.

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNODERMATOLOGY MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL IMMUNODERMATOLOGY MARKET FOR SYSTEMIC SCLEROSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL IMMUNODERMATOLOGY MARKET FOR DERMATOMYOSITIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL IMMUNODERMATOLOGY MARKET FOR PSORIASIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL IMMUNODERMATOLOGY MARKET FOR VITILIGO, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL IMMUNODERMATOLOGY MARKET FOR ALOPECIA AREATA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL IMMUNODERMATOLOGY MARKET FOR LICHEN SCLEROSUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL IMMUNODERMATOLOGY MARKET FOR ALLERGIC DERMATITIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL IMMUNODERMATOLOGY MARKET FOR ATOPIC DERMATITIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL IMMUNODERMATOLOGY MARKET FOR LUPUS ERYTHEMATOSUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL IMMUNODERMATOLOGY MARKET FOR BLISTERING DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL IMMUNODERMATOLOGY MARKET FOR CONNECTIVE TISSUE DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL IMMUNODERMATOLOGY MARKET, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL IMMUNODERMATOLOGY MARKET FOR IMMUNOFLUORESCENCE TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL IMMUNODERMATOLOGY MARKET FOR BIOPSY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL IMMUNODERMATOLOGY MARKET FOR BLOOD TEST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL IMMUNODERMATOLOGY MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL IMMUNODERMATOLOGY MARKET FOR DRUG THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL IMMUNODERMATOLOGY MARKET FOR INTENSED PULSED LIGHT (IPL)THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL IMMUNODERMATOLOGY MARKET FOR STEM CELL THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL IMMUNODERMATOLOGY MARKET FOR GENE THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. GLOBAL IMMUNODERMATOLOGY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 23. GLOBAL IMMUNODERMATOLOGY MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. GLOBAL IMMUNODERMATOLOGY MARKET FOR TOPICAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 25. GLOBAL IMMUNODERMATOLOGY MARKET FOR INTRAVENOUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 26. GLOBAL IMMUNODERMATOLOGY MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 27. NORTH AMERICA IMMUNODERMATOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 28. NORTH AMERICA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 29. NORTH AMERICA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 30. NORTH AMERICA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 31. NORTH AMERICA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 32. U.S. IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 33. U.S. IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 34. U.S. IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 35. U.S. IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 36. CANADA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. CANADA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 38. CANADA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 39. CANADA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 40. MEXICO IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. MEXICO IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 42. MEXICO IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 43. MEXICO IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 44. EUROPE IMMUNODERMATOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 45. EUROPE IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. EUROPE IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 47. EUROPE IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 48. EUROPE IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 49. FRANCE IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. FRANCE IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 51. FRANCE IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 52. FRANCE IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 53. GERMANY IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. GERMANY IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 55. GERMANY IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 56. GERMANY IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 57. ITALY IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 58. ITALY IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 59. ITALY IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 60. ITALY IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 61. SPAIN IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 62. SPAIN IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 63. SPAIN IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 64. SPAIN IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 65. UK IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 66. UK IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 67. UK IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 68. UK IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 69. RUSSIA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 70. RUSSIA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 71. RUSSIA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 72. RUSSIA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. REST OF EUROPE IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 74. REST OF EUROPE IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 75. REST OF EUROPE IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 76. REST OF EUROPE IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 77. ASIA-PACIFIC IMMUNODERMATOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 78. ASIA-PACIFIC IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 79. ASIA-PACIFIC IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 80. ASIA-PACIFIC IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 81. ASIA-PACIFIC IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 82. CHINA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 83. CHINA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 84. CHINA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 85. CHINA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 86. JAPAN IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 87. JAPAN IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 88. JAPAN IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 89. JAPAN IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 90. INDIA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 91. INDIA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 92. INDIA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 93. INDIA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH KOREA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH KOREA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH KOREA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH KOREA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 98. AUSTRALIA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 99. AUSTRALIA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 100. AUSTRALIA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 101. AUSTRALIA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 102. THAILAND IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 103. THAILAND IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 104. THAILAND IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 105. THAILAND IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 106. MALAYSIA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 107. MALAYSIA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 108. MALAYSIA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 109. MALAYSIA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 110. INDONESIA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 111. INDONESIA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 112. INDONESIA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 113. INDONESIA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 114. REST OF ASIA PACIFIC IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 115. REST OF ASIA PACIFIC IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 116. REST OF ASIA PACIFIC IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 117. REST OF ASIA PACIFIC IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 118. LAMEA IMMUNODERMATOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 119. LAMEA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 120. LAMEA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 121. LAMEA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 122. LAMEA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 123. BRAZIL IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 124. BRAZIL IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 125. BRAZIL IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 126. BRAZIL IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 127. SOUTH AFRICA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 128. SOUTH AFRICA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 129. SOUTH AFRICA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 130. SOUTH AFRICA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 131. SAUDI ARABIA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 132. SAUDI ARABIA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 133. SAUDI ARABIA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 134. SAUDI ARABIA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 135. UAE IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 136. UAE IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 137. UAE IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 138. UAE IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 139. ARGENTINA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 140. ARGENTINA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 141. ARGENTINA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 142. ARGENTINA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 143. REST OF LAMEA IMMUNODERMATOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 144. REST OF LAMEA IMMUNODERMATOLOGY, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 145. REST OF LAMEA IMMUNODERMATOLOGY, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 146. REST OF LAMEA IMMUNODERMATOLOGY, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 147. NOVARTIS: KEY EXECUTIVES
  • TABLE 148. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 149. NOVARTIS: OPERATING SEGMENTS
  • TABLE 150. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 151. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. ABBVIE: KEY EXECUTIVES
  • TABLE 153. ABBVIE: COMPANY SNAPSHOT
  • TABLE 154. ABBVIE: OPERATING SEGMENTS
  • TABLE 155. ABBVIE: PRODUCT PORTFOLIO
  • TABLE 156. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. VALEANT PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 158. VALEANT PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 159. VALEANT PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 160. VALEANT PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 161. VALEANT PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162. BAUSCH HEALTH: KEY EXECUTIVES
  • TABLE 163. BAUSCH HEALTH: COMPANY SNAPSHOT
  • TABLE 164. BAUSCH HEALTH: OPERATING SEGMENTS
  • TABLE 165. BAUSCH HEALTH: PRODUCT PORTFOLIO
  • TABLE 166. BAUSCH HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 167. GLENMARK PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 168. GLENMARK PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 169. GLENMARK PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 170. GLENMARK PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 171. GLENMARK PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 172. ASTELLAS PHARMA: KEY EXECUTIVES
  • TABLE 173. ASTELLAS PHARMA: COMPANY SNAPSHOT
  • TABLE 174. ASTELLAS PHARMA: OPERATING SEGMENTS
  • TABLE 175. ASTELLAS PHARMA: PRODUCT PORTFOLIO
  • TABLE 176. ASTELLAS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 177. NOVOPHARM LIMITED: KEY EXECUTIVES
  • TABLE 178. NOVOPHARM LIMITED: COMPANY SNAPSHOT
  • TABLE 179. NOVOPHARM LIMITED: OPERATING SEGMENTS
  • TABLE 180. NOVOPHARM LIMITED: PRODUCT PORTFOLIO
  • TABLE 181. NOVOPHARM LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 182. ASPEN PHARMACARE INC.: KEY EXECUTIVES
  • TABLE 183. ASPEN PHARMACARE INC.: COMPANY SNAPSHOT
  • TABLE 184. ASPEN PHARMACARE INC.: OPERATING SEGMENTS
  • TABLE 185. ASPEN PHARMACARE INC.: PRODUCT PORTFOLIO
  • TABLE 186. ASPEN PHARMACARE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 187. PROMETHEUS LABORATORIES: KEY EXECUTIVES
  • TABLE 188. PROMETHEUS LABORATORIES: COMPANY SNAPSHOT
  • TABLE 189. PROMETHEUS LABORATORIES: OPERATING SEGMENTS
  • TABLE 190. PROMETHEUS LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 191. PROMETHEUS LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 192. TARO PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 193. TARO PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 194. TARO PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 195. TARO PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 196. TARO PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNODERMATOLOGY MARKET SEGMENTATION
  • FIGURE 2. GLOBAL IMMUNODERMATOLOGY MARKET
  • FIGURE 3. SEGMENTATION IMMUNODERMATOLOGY MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN IMMUNODERMATOLOGY MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIMMUNODERMATOLOGY MARKET
  • FIGURE 11. IMMUNODERMATOLOGY MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. IMMUNODERMATOLOGY MARKET FOR SYSTEMIC SCLEROSIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. IMMUNODERMATOLOGY MARKET FOR DERMATOMYOSITIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. IMMUNODERMATOLOGY MARKET FOR PSORIASIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. IMMUNODERMATOLOGY MARKET FOR VITILIGO, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. IMMUNODERMATOLOGY MARKET FOR ALOPECIA AREATA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. IMMUNODERMATOLOGY MARKET FOR LICHEN SCLEROSUS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. IMMUNODERMATOLOGY MARKET FOR ALLERGIC DERMATITIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. IMMUNODERMATOLOGY MARKET FOR ATOPIC DERMATITIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. IMMUNODERMATOLOGY MARKET FOR LUPUS ERYTHEMATOSUS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. IMMUNODERMATOLOGY MARKET FOR BLISTERING DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. IMMUNODERMATOLOGY MARKET FOR CONNECTIVE TISSUE DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. IMMUNODERMATOLOGY MARKET SEGMENTATION, BY BY DIAGNOSIS
  • FIGURE 24. IMMUNODERMATOLOGY MARKET FOR IMMUNOFLUORESCENCE TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. IMMUNODERMATOLOGY MARKET FOR BIOPSY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. IMMUNODERMATOLOGY MARKET FOR BLOOD TEST, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. IMMUNODERMATOLOGY MARKET SEGMENTATION, BY BY THERAPY
  • FIGURE 28. IMMUNODERMATOLOGY MARKET FOR DRUG THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. IMMUNODERMATOLOGY MARKET FOR INTENSED PULSED LIGHT (IPL)THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. IMMUNODERMATOLOGY MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 31. IMMUNODERMATOLOGY MARKET FOR GENE THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 32. IMMUNODERMATOLOGY MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 33. IMMUNODERMATOLOGY MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 34. IMMUNODERMATOLOGY MARKET FOR TOPICAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 35. IMMUNODERMATOLOGY MARKET FOR INTRAVENOUS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 36. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 39. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 40. COMPETITIVE DASHBOARD
  • FIGURE 41. COMPETITIVE HEATMAP: IMMUNODERMATOLOGY MARKET
  • FIGURE 42. Top player positioning, 2022
  • FIGURE 43. NOVARTIS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. NOVARTIS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. NOVARTIS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. ABBVIE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. ABBVIE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. ABBVIE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. VALEANT PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. VALEANT PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. VALEANT PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. BAUSCH HEALTH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. BAUSCH HEALTH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. BAUSCH HEALTH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. GLENMARK PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. GLENMARK PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. GLENMARK PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. ASTELLAS PHARMA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. ASTELLAS PHARMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. ASTELLAS PHARMA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. NOVOPHARM LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. NOVOPHARM LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. NOVOPHARM LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 64. ASPEN PHARMACARE INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. ASPEN PHARMACARE INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 66. ASPEN PHARMACARE INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 67. PROMETHEUS LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. PROMETHEUS LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 69. PROMETHEUS LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 70. TARO PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. TARO PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 72. TARO PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Immunodermatology Market

Start reading.
This Report and over 68,439+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers